The overall role of the Administrative Core is to oversee the operation of the CF Center. The Administrative Core coordinates Core functions. Center-related meetings, enrichment, training and communications that all require an infrastructure with centralized operations to function well. CF Center research is the beneficiary of this coordination. Dr. Mitchell Drumm will direct the administrative duties, assisted by Ms. Connie May. The responsibilities will include decisions regarding allocations of Center resources (core availability, pilot and feasibility allocation, etc.), implementation of an effective enrichment program, development and maintenance of a CF Center-specific website and to preside over the Center executive committee.
The aims of the Administrative Core are: 1) To coordinate activities of the Center 2) To allocate resources of the Center 3) To provide administrative and clerical assistance for Center-related activities 4) To provide pilot and feasibility opportunities to young investigators embarking on CF-related research, or more senior investigators entering CF research or proposing to change direction in CF. 5) To plan and execute an enrichment program consisting of seminars by local and guest faculty lecturers, as well as by trainees in the Center
The scope and size of our Center requires an infrastructure to coordinate activities and to oversee that the basic and clinical research projects are designed and conducted in a manner that results in meaningful research and contributes to the overall mission of the Center.
|Dasenbrook, Elliott C; Konstan, Michael W; VanDevanter, Donald R (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14:370-5|
|Than, B L N; Goos, J A C M; Sarver, A L et al. (2014) The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 33:3861-8|
|Xu, Weiling; Janocha, Allison J; Leahy, Rachel A et al. (2014) A novel method for pulmonary research: assessment of bioenergetic function at the air-liquid interface. Redox Biol 2:513-9|
|Boyle, Michael P; Bell, Scott C; Konstan, Michael W et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:527-38|
|Doring, Gerd; Bragonzi, Alessandra; Paroni, Moira et al. (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13:156-63|
|Spilker, Theodore; Leber, Amy L; Marcon, Mario J et al. (2014) A simplified sequence-based identification scheme for Bordetella reveals several putative novel species. J Clin Microbiol 52:674-7|
|Zaman, Khalequz; Bennett, Deric; Fraser-Butler, Maya et al. (2014) S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface. Biochem Biophys Res Commun 443:1257-62|
|VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2014) Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. J Pediatr 165:1091-1097.e2|
|Caretti, Anna; Bragonzi, Alessandra; Facchini, Marcella et al. (2014) Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. Biochim Biophys Acta 1840:586-94|
|Kerem, Eitan; Konstan, Michael W; De Boeck, Kris et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2:539-47|
Showing the most recent 10 out of 274 publications